A Phase III, double-blind, placebo-controlled study of FSN-013 for treatment of Japanese patients with dysmenorrhea.
Latest Information Update: 09 Aug 2023
Price :
$35 *
At a glance
- Drugs Drospirenone/estetrol (Primary)
- Indications Dysmenorrhoea
- Focus Registrational; Therapeutic Use
- Sponsors Fuji Pharmaceutical
- 09 Aug 2023 New trial record